Catheter Precision, Inc.
VTAKCatheter Precision, Inc. (VTAK) is a medical device company focused on developing innovative, minimally invasive catheter technologies for various therapeutic applications. The company aims to enhance procedural outcomes and patient safety through precision-engineered products designed for cardiovascular and other clinical interventions.
Company News
Catheter Precision has signed a strategic distribution agreement with FuMedica AG to introduce its LockeT suture retention device to hospitals and clinics across Switzerland, marking an important step in the company's European expansion strategy.
Catheter Precision announced receiving two patent allowances from the USPTO: one for ventricular arrhythmia localization using a 3D model, and another for neurostimulation devices aimed at improving cardiac ventricular function.
Catheter Precision received its first purchase order from Dubrava University Hospital in Croatia after a successful product evaluation of its VIVO 3D imaging system for cardiac arrhythmia procedures.
Catheter Precision, Inc. implemented a 1-for-19 reverse stock split, reducing its outstanding shares from 23,316,520 to approximately 1,657,640. The split became effective on August 15, 2025, and will continue trading under the VTAK symbol on NYSE American.
Catheter Precision, a US-based medical device company, has received CE Mark approval for its LockeT vascular closure device, making it eligible for sale in the European Union and other countries. This approval opens up a multi-billion dollar market opportunity, with the European vascular closure devices market expected to grow to $4.3 billion by ...
